Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, being held September 3-6, 2024 in Porto, Portugal.

Poster Sessions:

Fabry Disease:

Abstract Title: FollowME Fabry Pathfinders registry: patient-reported outcomes in a cohort of patients on migalastat treatment for at least two years (Poster #21180)

  • Presenter: Aleš Linhart, D.Sc., Charles University and General University Hospital in Prague, Prague, Czech Republic
  • Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
  • Location: Poster Room, Rosa Mota Pavilion

Abstract Title: Quality of life of migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension (Poster #21202)

  • Presenter: Amarilis Sanchez-Valle, MD, University of South Florida Health, Tampa, U.S.A.
  • Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
  • Location: Poster Room, Rosa Mota Pavilion

Abstract Title: Exploring the journey of patients living with Fabry disease in Poland (Poster #20789)

  • Presenter: Anna Moskal, The Association of Families with Fabry Disease, Wroclaw, Poland
  • Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
  • Location: Poster Room, Rosa Mota Pavilion

Pompe Disease:

Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #20863)

  • Presenter: Elaine Murphy, MD, University College London Hospitals, London, U.K.
  • Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
  • Guided Poster Walk: Thursday, September 5, 12:10 – 1:40 p.m. WET
  • Location: Poster Room, Rosa Mota Pavilion

Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #20873)

  • Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
  • Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
  • Location: Poster Room, Rosa Mota Pavilion

For more information on the SSIEM 2024 Annual Symposium, please visit ssiem2024.org.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.